Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Castagna

Showing results (21-30 of 93) with videos related to

Pageof 10
Sort By:
Journal of Personalized Medicine|March 25, 2022
The Role of Tumor Necrosis Factor Alpha Antagonists (Anti TNF-α) in Personalized Treatment of Patients with Isolated Polymyalgia Rheumatica (PMR): Past and Possible Future ScenariosCiro Manzo, Elvis Hysa, Alberto Castagna, et al.
Rheumatology (Oxford, England)|May 8, 2024
Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirementCiro Manzo, Maria Natale, Marco Isetta, et al.
Clinical and Experimental Rheumatology|February 26, 2021
Calcium pyrophosphate disease and polymyalgia reumatica: association or coincidence? Comment on "Ultrasound shoulder assessment of calcium pyrophosphate disease with suspected polymyalgia rheumatica" Ottaviani et alMarcin Milchert, Ciro Manzo, Alberto Castagna, et al.
Medical Sciences (Basel, Switzerland)|April 23, 2025
Polymyalgia Rheumatica (PMR) and Polymyalgia Rheumatica-like (PMR-like) Manifestations in Cancer Patients Following Treatment with Nivolumab and Pembrolizumab: Methodological Blurred Points Identified Through a Systematic Review of Published Case ReportsCiro Manzo, Marco Isetta, Alberto Castagna, et al.
Joint Bone Spine|October 3, 2021
Answer to Cadiou et al. "SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger?". Joint Bone Spine 2021;88:105282Ciro Manzo, Alberto Castagna, Maria Natale, et al.
Reumatologia|November 16, 2023
Polymyalgia rheumatica and polymyalgia-like syndromes as adverse events following immunisation with COVID-19 vaccines: a 15 months updateCiro Manzo, Alberto Castagna, Arvind Nune, et al.
Reumatologia|February 7, 2024
Presence of subclinical giant cell arteritis in patients with morning stiffness of duration less than 45 minutes at the time of diagnosis of polymyalgia rheumaticaCiro Manzo, Alberto Castagna, Nicola Veronese, et al.
Clinical and Experimental Rheumatology|January 31, 2023
The management of patients with polymyalgia rheumatica: limitations to get it rightCiro Manzo, Maria Natale, Arvind Nune, et al.
Medical Hypotheses|January 10, 2021
Could COVID-19 anosmia and olfactory dysfunction trigger an increased risk of future dementia in patients with ApoE4?Ciro Manzo, Jordi Serra-Mestres, Marco Isetta, et al.
Medicines (Basel, Switzerland)|August 4, 2018
Behavioral, Psychiatric, and Cognitive Adverse Events in Older Persons Treated with GlucocorticoidsCiro Manzo, Jordi Serra-Mestres, Alberto Castagna, et al.
Pageof 10

Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
Journal of Personalized Medicine|March 25, 2022
The Role of Tumor Necrosis Factor Alpha Antagonists (Anti TNF-α) in Personalized Treatment of Patients with Isolated Polymyalgia Rheumatica (PMR): Past and Possible Future ScenariosCiro Manzo, Elvis Hysa, Alberto Castagna, et al.
Rheumatology (Oxford, England)|May 8, 2024
Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirementCiro Manzo, Maria Natale, Marco Isetta, et al.
Clinical and Experimental Rheumatology|February 26, 2021
Calcium pyrophosphate disease and polymyalgia reumatica: association or coincidence? Comment on "Ultrasound shoulder assessment of calcium pyrophosphate disease with suspected polymyalgia rheumatica" Ottaviani et alMarcin Milchert, Ciro Manzo, Alberto Castagna, et al.
Medical Sciences (Basel, Switzerland)|April 23, 2025
Polymyalgia Rheumatica (PMR) and Polymyalgia Rheumatica-like (PMR-like) Manifestations in Cancer Patients Following Treatment with Nivolumab and Pembrolizumab: Methodological Blurred Points Identified Through a Systematic Review of Published Case ReportsCiro Manzo, Marco Isetta, Alberto Castagna, et al.
Joint Bone Spine|October 3, 2021
Answer to Cadiou et al. "SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger?". Joint Bone Spine 2021;88:105282Ciro Manzo, Alberto Castagna, Maria Natale, et al.
Reumatologia|November 16, 2023
Polymyalgia rheumatica and polymyalgia-like syndromes as adverse events following immunisation with COVID-19 vaccines: a 15 months updateCiro Manzo, Alberto Castagna, Arvind Nune, et al.
Reumatologia|February 7, 2024
Presence of subclinical giant cell arteritis in patients with morning stiffness of duration less than 45 minutes at the time of diagnosis of polymyalgia rheumaticaCiro Manzo, Alberto Castagna, Nicola Veronese, et al.
Clinical and Experimental Rheumatology|January 31, 2023
The management of patients with polymyalgia rheumatica: limitations to get it rightCiro Manzo, Maria Natale, Arvind Nune, et al.
Medical Hypotheses|January 10, 2021
Could COVID-19 anosmia and olfactory dysfunction trigger an increased risk of future dementia in patients with ApoE4?Ciro Manzo, Jordi Serra-Mestres, Marco Isetta, et al.
Medicines (Basel, Switzerland)|August 4, 2018
Behavioral, Psychiatric, and Cognitive Adverse Events in Older Persons Treated with GlucocorticoidsCiro Manzo, Jordi Serra-Mestres, Alberto Castagna, et al.
Pageof 10